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Abstract: As the underlying pathogen for the COVID-19 pandemic that has affected tens of millions of lives worldwide, SARS-CoV-2
and its mutations are among the most urgent research topics worldwide. Mutations in the virus genome can complicate attempts at
accurate testing or developing a working treatment for the disease. Furthermore, because the virus uses its own proteins to replicate its
genome, rather than host proteins, mutations in the replication proteins can have cascading effects on the mutation load of the virus
genome. Due to the global, rapidly developing nature of the COVID-19 pandemic, local demographics of the virus can be difficult to
accurately analyze and track, disproportionate to the importance of such information. Here, we analyzed available, high-quality genome
data of SARS-CoV-2 isolates from Turkey and identified their mutations, in comparison to the reference genome, to understand how
the local mutatome compares to the global genomes. Our results indicate that viral genomes in Turkey has one of the highest mutation
loads and certain mutations are remarkably frequent compared to global genomes. We also made the data on Turkey isolates available
on an online database to facilitate further research on SARS-CoV-2 mutations in Turkey.
Key words: COVID-19, SARS-CoV-2, coronavirus, genome analysis, mutation profiling, Turkey, database

1. Introduction
Coronavirus disease 2019 (COVID-19) is an ongoing
pandemic, characterized by long-term respiratory
damage and slow onset fever, and caused by the SARSCoV-2 betacoronavirus. The virus was first observed in
human patients in late 2019, in the Wuhan province of
China, and soon after showed the capacity for humanto-human transmission (Chan et al., 2020; Riou and
Althaus, 2020). As of 17 August 2020 there are over 21
million confirmed cases and 767,158 recorded deaths1. In
addition to the immediately apparent symptoms, its long
term effect on humans are still topics of research (Kochi et
al., 2020; Lee et al., 2020; Li et al., 2020; Zhu et al., 2020).
Because COVID-19 is a highly transmissible disease with
a capacity for asymptomatic transmission (Wong et al.,
2020); understanding the disease, as well as its underlying
pathogen and its routes of transmissions is a high priority
topic. As a result, extant databases on viral pathogens,
such as GISAID2 (Elbe and Buckland‐Merrett, 2017)
1
World Health Organization (1948). WHO timeline – COVID-19
[online]. Website https://www.who.int/news-room/detail/27-042020-who-timeline---covid-19 [accessed 17 August 2020].
2
The GISAID Initiative (2008). GISAID [online]. Website https://
www.gisaid.org/ [accessed 27 August 2020].

and Nextstrain3 (Hadfield et al., 2018) have become vital
resources for researchers who seek to track the evolution
of the virus during its transmissions.
SARS-CoV-2 has a single-stranded RNA genome that
codes for the proteins responsible for its own replication,
many of which are produced via cleavage of the Orf1ab
polyprotein, the largest gene on the genome. Therefore,
mutations in the SARS-CoV-2 genome can lead to
cascading effects by reducing the fidelity of subsequent
replication cycles. Key proteins in the RNA replication
complex include nsps 7, 8, and 12 (also known as RNA
dependent RNA polymerase or RdRp), which together
form the core polymerase complex (Kirchdoerfer and
Ward 2019; Peng et al., 2020), as well as nsp14, a dual
function protein which joins the larger replication complex
as a 3’-5’ error-correcting exonuclease (Subissi et al., 2014;
Romano et al., 2020). Our previous findings show that
frequently observed mutations in both nsp12 and nsp14
are associated with an increase in mutation density in the
SARS-CoV-2 genome (Eskier et al., 2020a, 2020b, 2020c).
In this study, we aimed to analyze the current
mutatome of SARS-CoV-2 in Turkey, with three main

Nextstrain (2015). Nextstrain [online]. Website https://www.
nextstrain.org [accessed 27 August 2020].
3
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questions in mind: (i) are there any key reoccurring
mutations observed in a large number of isolates? (ii) how
does the distribution of mutations among isolates compare
to other regions in the world? and finally, (iii) are there any
mutations observed in Turkey but not the rest of the world?
We focused on the latter two questions in particular, with
an emphasis on mutations of interest previously described
in the literature. Our findings reveal the presence of three
main clades of SARS-CoV-2 in Turkey, roughly analogous
to 19A, 20A, and 20B as described in NextStrain, with a
preponderance of high mutability variants (Eskier et al.,
2020a, 2020b, 2020c) compared to international isolates.
Furthermore, we identified several frequently recurrent,
previously uncharacterized variants in Turkey isolates
not observed in isolates from other countries, which can
serve as potential candidates for validation and study.
Furthermore, we collected our analysis of Turkey isolates
in a regularly maintained and updated database, which we
hope will serve as a potential resource for future research
on the local mutatome of SARS-CoV-2.
2. Materials and methods
2.1. Genome sequence filtering, retrieval, and
preprocessing
SARS-CoV-2 isolate genome sequences and the
corresponding metadata were obtained from the GISAID
EpiCoV database on 28 July 20204. These sequences
were filtered for location to limit our database to isolates
with the location “Europe/Turkey”, which resulted in
180 isolate sequences. We applied further quality filters,
including selecting only isolates obtained from human
hosts (excluding environmental samples and animal
hosts), those sequenced for the full length of the genome
(sequence size of 29 kb or greater), and those with high
coverage for the reference genome (<1% N content, < 0.05%
unique mutations, no unverified indel mutations), which
further narrowed down the list to 166 isolates. To ensure
alignment accuracy, as characters that are not one of A,
C, G, T, or N would not be aligned according to potential
biological meanings of the alternative characters, all
nonstandard unverified nucleotide masking was changed
to N, using the Linux sed command, and the isolates
were aligned against the SARS-CoV-2 reference genome
using the MAFFT (v7.450) alignment software (Katoh
et al., 2002). Variant sites in the isolates were annotated
using snp-sites (2.5.1), bcftools (1.10.2)5, and ANNOVAR
(release date 24 October 2019) software (Wang et al., 2010;
Page et al., 2016), to identify whether a given mutation
was synonymous or nonsynonymous. In addition, the
4
The GISAID Initiative (2008). EpiCoV database [online].
Website https://www.epicov.org/epi3/frontend [accessed 28 July
2020].
5
GitHub (2007). Bcftools repository [online]. Website https://
github.com/samtools/bcftools [accessed 20 August 2020].

5’ untranslated region of the genome (bases 1–265) and
the 100 nucleotides at the 3’ end were removed from the
alignment and annotation files due to a high number of
gaps and unidentified nucleotides.
2.2. Development of the database and user interfaces
The genome data is stored using the MariaDB 10.3.22
database installed on Debian Linux 10 operating system.
For web application, the genome data is visualized on
the map using jVectorMap with HTML 5 and Ajax
web development techniques, using the Django 3.0.5.
framework and Python 3.7.3 programming language.
A modified version of TreeTime, an open-source
phylogenetic analysis software, is used to create the
phylogenetic tree (Sagulenko et al., 2018).
3. Results
3.1. The distributions of mutations across isolates in
Turkey
Our analysis of the genome sequences of 166 isolates
from Turkey revealed 258 distinct mutations across the
isolates, 87 of which are observed in multiple isolates,
and 43 of them are found in at least five isolates (hereafter
referred to as recurring mutations). 19 of the 43 recurring
mutations are nonsynonymous, 21 are synonymous, and
3 are found outside of coding regions. C>T transitions are
the most common, comprising over half of the mutations,
consistent with previous international findings on C>U
hypermutations in SARS-CoV-2 (Simmonds, 2020). The
most commonly seen mutations are 3037 C>T, 14408 C>T,
and 23403 A>G, observed together in 139 of the isolates,
with one singleton instance of 23403 A>G, also consistent
with previous findings (Pachetti et al., 2020; Yin, 2020).
Orf1ab mutations are the most common, comprising 23
of the recurring mutations, consistent with the size of
the gene, as Orf1ab makes up two thirds of the SARSCoV-2 genome. Orf9 (nucleocapsid; N) gene has the
second highest number of recurring mutations (n = 7,
however, 3 of them are block mutations of 28881–28883
trinucleotide), followed by Orf5 (membrane; M) and S
genes (n = 5) (Table 1).
To identify which of the recurring mutations are
stronger indicators of Turkey genotype, we compared
their frequency in the isolate population from Turkey to
frequencies in other geographical regions, using a metric
of mutation instance per sequenced isolate. To eliminate
the potential confounding effect of earlier isolates having
a lower number of mutations on average, and different
regions having started sequencing efforts in different
timetables, we selected isolates sequenced after the day
when each region of interest had at least ten isolates
sequenced. As Turkey was the latest region to have the
required number of isolates (19 March 2020), it was used
as the filtering metric. Four of the recurring mutations
were found only in Turkey isolates, and six more were not
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Table 1. Recurring mutations in Turkey.
Position Reference Variant Frequency Cities
İstanbul (65), Karaman (1), Kastamonu (1),
Nevşehir (2), Ankara (13), Kocaeli (5), Siirt
(1), Aksaray (1), Sakarya (3), Afyon (1), Balıkesir
(1), Konya (1), Denizli (2), Tekirdağ (1), Tokat (1),
Kars (41)
İstanbul (65), Karaman (1), Kastamonu (1),
Nevşehir (2), Ankara (13), Kocaeli (4), Siirt
(1), Aksaray (1), Sakarya (3), Afyon (1), Balıkesir
(1), Konya (1), Denizli (2), Tekirdağ (1), Tokat (1),
Kars (41)
İstanbul (65), Karaman (1), Kastamonu (1),
Nevşehir (2), Ankara (13), Kocaeli (4), Siirt
(1), Aksaray (1), Sakarya (3), Afyon (1), Balıkesir
(1), Konya (1), Denizli (2), Tekirdağ (1), Tokat (1),
Kars (41)
İstanbul (66), Nevşehir (1), Kocaeli (3),
Ankara (6), Denizli (1), Ağrı (1), Tekirdağ (1),
Tokat (1), Kars (41)
İstanbul (40), Sakarya (2), Kocaeli (3),
Ankara (3), Kars (25)
İstanbul (40), Sakarya (2), Kocaeli (3),
Ankara (3), Kars (25)
İstanbul (40), Sakarya (2), Kocaeli (3),
Ankara (3), Kars (25)
İstanbul (24), Karaman (1), Kastamonu (1),
Nevşehir (2), Ankara (8), Kocaeli (1), Siirt (1),
Aksaray (1), Sakarya (1), Afyon (1), Balıkesir (1),
Konya (1), Tekirdağ (1), Tokat (1), Kars (16)
İstanbul (24), Kastamonu (1), Nevşehir (2),
Ankara (7), Kocaeli (1), Siirt (1), Aksaray (1),
Sakarya (1), Afyon (1), Balıkesir (1), Konya
(1), Tekirdağ (1), Tokat (1), Kars (15)
İstanbul (18), Siirt (1), Nevşehir (1), Tekirdağ (1),
Kars (14)
İstanbul (18), Siirt (1), Nevşehir (1), Tekirdağ (1),
Kars (14)
Kayseri (1), İstanbul (11), Karaman (1),
Ankara (6), Balıkesir (1), Çanakkale (1), Eskişehir
(1), Kocaeli (4), Mardin (1), Ağrı (1), Kars (3)
Kayseri (1), Ankara (5), Kocaeli (5), Balıkesir (1),
Çanakkale (1), Eskişehir (1), Mardin (1), İstanbul
(8), Ağrı (1)
Kayseri (1), Ankara (5), Balıkesir (1), Çanakkale
(1), Eskişehir (1), Kocaeli (4), Mardin (1),
İstanbul (8), Ağrı (1)

23403

A

G

140

3037

C

T

139

14408

C

T

139

241

C

T

121

28881

G

A

73

28882

G

A

73

28883

G

C

73

25563

G

T

61

18877

C

T

58

7765

C

T

35

17690

C

T

35

11083

G

T

31

29742

G

T

24

1397

G

A

23

12809

C

T

23

İstanbul (20), Kars (3)

28688

T

C

23

Kayseri (1), Ankara (5), Balıkesir (1), Çanakkale
(1), Eskişehir (1), Kocaeli (4), Mardin (1),
İstanbul (8), Ağrı (1)

27703

G

T

20

Kars (20)
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Exonic function

Gene

Aminoacid
change

Nonsynonymous
SNV

S

p.D614G

Synonymous SNV

ORF1a;
ORF1ab

p.F924F

Nonsynonymous
SNV

ORF1ab

p.P4715L

ORF1a;
ORF1ab
Nonsynonymous
SNV

ORF9

p.R203K

Synonymous SNV ORF9

p.R203R

Nonsynonymous
SNV

ORF9

p.G204R

Nonsynonymous
SNV

ORF3a

p.Q57H

Synonymous SNV ORF1ab

p.L6205L

Synonymous SNV

ORF1a;
ORF1ab

p.S2500S

Nonsynonymous
SNV

ORF1ab

p.S5809L

Nonsynonymous
SNV

ORF1a;
ORF1ab

p.L3606F

ORF10;
ORF9
Nonsynonymous
SNV

ORF1a;
ORF1ab

p.V378I

Nonsynonymous
SNV

ORF1a;
ORF1ab

p.L4182F

Synonymous SNV ORF9

p.L139L

Nonsynonymous
SNV

p.V104F

ORF7a
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Table 1. (Continued).
Position Reference Variant Frequency Cities

Exonic function

Gene

Aminoacid
change

24262

G

T

20

Kars (20)

Nonsynonymous
SNV

S

p.M900I

313

C

T

19

Kars (19)

2509

C

T

19

Kars (19)

13620

C

T

19

Kars (19)

Synonymous SNV ORF1ab

p.D4452D

14724

C

T

19

Kars (19)

Synonymous SNV ORF1ab

p.F4820F

19839

T

C

18

Ankara (2), İstanbul (15), Kars (1)

Synonymous SNV ORF1ab

p.N6525N

26735

C

T

15

8326

C

T

14

2113

C

T

13

884

C

T

12

8653

G

T

12

26549

C

T

12

5015

G

A

11

28854

C

T

10

228

C

T

9

22444

C

T

9

9514

A

G

8

26720

G

C

8

Kocaeli (1), İstanbul (4), Ağrı (1), Ankara (2)

9479

G

T

7

Kocaeli (1), İstanbul (4), Ağrı (1), Ankara (1)

28835

T

C

7

Kocaeli (1), İstanbul (4), Ağrı (1), Ankara (1)

5736

C

T

6

Ankara (3), Denizli (1), İstanbul (2)

16428

C

T

6

25611

C

A

28857

G

10702
20268

ORF1a;
ORF1ab
ORF1a;
Synonymous SNV
ORF1ab
Synonymous SNV

Kastamonu (1), Nevşehir (1), Ankara (5), Kocaeli
(1), Aksaray (1), Sakarya (1), Afyon (1), Balıkesir Synonymous SNV ORF5
(1), Konya (1), İstanbul (2)
ORF1a;
Kars (14)
Synonymous SNV
ORF1ab
ORF1a;
İstanbul (11), Nevşehir (1), Tekirdağ (1)
Synonymous SNV
ORF1ab
Balıkesir (1), Çanakkale (1), Eskişehir (1), Kocaeli Nonsynonymous ORF1a;
(3), Ankara (3), İstanbul (3)
SNV
ORF1ab
Balıkesir (1), Çanakkale (1), Eskişehir (1), Kocaeli Nonsynonymous ORF1a;
(3), Ankara (3), İstanbul (3)
SNV
ORF1ab
Kocaeli (2), İstanbul (5), Ankara (3), Tokat
Synonymous SNV ORF5
( 1), Denizli (1)
Nonsynonymous ORF1a;
Kars (11)
SNV
ORF1ab
Ankara (3), Aksaray (1), Sakarya (1), Konya (1), Nonsynonymous
ORF9
İstanbul (3), Kars (1)
SNV
ORF1a;
Kocaeli (1), İstanbul (4), Ankara (3), Denizli (1)
ORF1ab
Ankara (3), Aksaray (1), Sakarya (1), Konya (1),
Synonymous SNV S
İstanbul (3)
ORF1a;
Kocaeli (1), İstanbul (4), Ağrı (1), Ankara (2)
Synonymous SNV
ORF1ab
Synonymous SNV ORF5
Nonsynonymous
SNV
Nonsynonymous
SNV
Nonsynonymous
SNV

p.L16L
p.P748P

p.Y71Y
p.D2687D
p.I616I
p.R207C
p.M2796I
p.T9T
p.V1584M
p.S194L

p.D294D
p.L3083L
p.V66V

ORF1a;
ORF1ab

p.G3072C

ORF9

p.S188P

ORF1a;
ORF1ab

p.A1824V

Kars (6)

Synonymous SNV ORF1ab

p.Y5388Y

6

İstanbul (6)

Synonymous SNV ORF3a

p.L73L

T

6

Kars (6)

Nonsynonymous
SNV

ORF9

p.R195I

C

T

5

Eskişehir (1), Ankara (1), İstanbul (3)

Synonymous SNV

ORF1a;
ORF1ab

p.D3479D

A

G

5

Ankara (2), Denizli (1), Kocaeli (1), İstanbul (1)

Synonymous SNV ORF1ab

p.L6668L
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recurring mutations in other regions. Therefore, we focused
the comparisons on the remaining 33 recurring mutations.
We identified the percentages of these mutations in each
region (Africa, Asia, Europe, North America, Oceania,
South America), as well as worldwide totals, excluding
isolates from Turkey, where applicable, and compared
them to the corresponding percentages in Turkey (Table 2).
With two exceptions (241 C>T and 20268 A>G), all of the

mutations have higher percentages in Turkey compared to
worldwide percentages. In addition, isolates from Turkey
comprise over 50% of the isolates worldwide carrying six
of the mutations (228 C>T, 8326 C>T, 12809 C>T, 13620
C>T, 14724 C>T, and 27703 C>T), and 20 of the mutations
have higher percentages in Turkey than any other region.
Among these six mutations, 228 C>T was first detected in
Canada on March 11 and in Turkey (İstanbul) on March

Table 2. Frequencies of SARS-CoV-2 mutations in different geographical regions.
Mutation

Africa

Asia

Europe

North America Oceania

South America

Turkey

Worldwide

23403A>G

88.73% (252) 58.15% (835) 82.34% (10484) 78.15% (4470)

67.07% (894) 93.48% (258)

84.34% (140) 78.94% (17193)

3037C>T

79.58% (226) 58.84% (845) 82.03% (10444) 78.25% (4476)

66.99% (893) 93.48% (258)

83.73% (139) 78.7% (17142)

14408C>T

87.68% (249) 58.57% (841) 82.32% (10481) 78.36% (4482)

67.14% (895) 93.48% (258)

83.73% (139) 79% (17206)

241C>T

88.73% (252) 58.29% (837) 82.24% (10471) 77.36% (4425)

51.24% (683) 93.48% (258)

72.89% (121) 77.71% (16926)

28881G>A

22.18% (63)

16.92% (243) 38.73% (4931)

5.03% (288)

13.5% (180)

48.55% (134)

43.98% (73)

26.81% (5839)

28882G>A

22.18% (63)

16.85% (242) 38.68% (4925)

5.02% (287)

13.28% (177) 48.55% (134)

43.98% (73)

26.76% (5828)

28883G>C

22.18% (63)

16.92% (243) 38.67% (4924)

5.02% (287)

13.35% (178) 48.55% (134)

43.98% (73)

26.76% (5829)

25563G>T

10.21% (29)

26.46% (380) 12.21% (1554)

65.93% (3771)

28.21% (376) 30.8% (85)

36.75% (61)

28.44% (6195)

18877C>T

2.46% (7)

15.67% (225) 1.2% (153)

5.38% (308)

1.73% (23)

9.78% (27)

34.94% (58)

3.41% (743)

7765C>T

1.06% (3)

0.35% (5)

0.57% (73)

0.07% (4)

0.15% (2)

0% (0)

21.08% (35)

0.4% (87)

17690C>T

1.06% (3)

0.14% (2)

0.47% (60)

0.07% (4)

0.08% (1)

0% (0)

21.08% (35)

0.32% (70)

11083G>T

8.8% (25)

28.41% (408) 10.91% (1389)

3.22% (184)

15.68% (209) 5.07% (14)

18.67% (31)

10.23% (2229)

29742G>T

0.7% (2)

2.44% (35)

0.24% (14)

3.45% (46)

14.46% (24)

0.52% (114)

0.13% (17)

0% (0)

1397G>A

1.06% (3)

2.44% (35)

0.03% (4)

0.21% (12)

4.43% (59)

0% (0)

13.86% (23)

0.52% (113)

12809C>T

0% (0)

0% (0)

0.02% (3)

0.12% (7)

0% (0)

0% (0)

13.86% (23)

0.05% (10)

28688T>C

1.06% (3)

2.51% (36)

0.02% (3)

0.14% (8)

4.35% (58)

0% (0)

13.86% (23)

0.5% (108)

27703G>T

0% (0)

0% (0)

0.06% (8)

0% (0)

0.08% (1)

0% (0)

12.05% (20)

0.04% (9)

313C>T

0.7% (2)

4.81% (69)

1.56% (199)

0.72% (41)

0.75% (10)

0.36% (1)

11.45% (19)

1.48% (322)

13620C>T

0% (0)

0% (0)

0.04% (5)

0.03% (2)

0% (0)

0% (0)

11.45% (19)

0.03% (7)

14724C>T

0% (0)

0% (0)

0.07% (9)

0.12% (7)

0.08% (1)

0.36% (1)

11.45% (19)

0.08% (18)

19839T>C

0.7% (2)

0.63% (9)

2.37% (302)

0.59% (34)

0.38% (5)

0.36% (1)

10.84% (18)

1.62% (353)

26735C>T

0.35% (1)

14.35% (206) 0.57% (73)

0% (0)

0.6% (8)

0% (0)

9.04% (15)

1.32% (288)

8326C>T

0% (0)

0.07% (1)

0.03% (4)

0% (0)

0% (0)

0% (0)

8.43% (14)

0.02% (5)

2113C>T

0.7% (2)

0.14% (2)

0.49% (62)

0.03% (2)

0.08% (1)

0% (0)

7.83% (13)

0.32% (69)

884C>T

0.7% (2)

1.95% (28)

0.02% (3)

0.1% (6)

0.38% (5)

0% (0)

7.23% (12)

0.2% (44)

8653G>T

0.7% (2)

1.88% (27)

0.04% (5)

0.12% (7)

0.3% (4)

0% (0)

7.23% (12)

0.21% (45)

28854C>T

0.7% (2)

6.69% (96)

2.52% (321)

1.38% (79)

0.83% (11)

0.36% (1)

6.02% (10)

2.34% (510)

228C>T

0.35% (1)

0.07% (1)

0.02% (3)

0% (0)

0.08% (1)

0% (0)

5.42% (9)

0.03% (6)

22444C>T

0% (0)

6.48% (93)

0.02% (2)

0% (0)

0% (0)

0% (0)

5.42% (9)

0.44% (95)

9479G>T

0.35% (1)

0.14% (2)

0.07% (9)

0.05% (3)

0.15% (2)

0% (0)

4.22% (7)

0.08% (17)

16428C>T

0% (0)

0% (0)

0.01% (1)

0.12% (7)

0% (0)

0.36% (1)

3.61% (6)

0.04% (9)

28857G>T

0% (0)

0.07% (1)

0.09% (12)

0.02% (1)

0% (0)

0% (0)

3.61% (6)

0.06% (14)

20268A>G

3.17% (9)

1.04% (15)

8.18% (1042)

1.03% (59)

4.13% (55)

9.06% (25)

3.01% (5)

5.53% (1205)
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186. The 8326 C > T mutation was first isolated from a
patient in Taipei on March 19 and only two other cases
was reported (UK and Denmark) before the first case
in Turkey (Kars) on April 29. Thirteen more cases with
8326 C>T in the same city implicates local transmission,
and with 8 cases reported on the most recent update
(July 15), this particular mutation is a candidate for even
further spread, assuming that the isolates sequenced were
randomly selected across the infected population, instead
of all being selected from a known cluster of patients. The
12809 C>T mutation was first reported in an isolate from
Washington/USA collected on March 14, which spread to
five more states by the end of the month; however, only
4 more cases were reported afterwards, the last being
one on April 27. The first isolate from Turkey with 12809
C>T mutation was collected on April 13 in İstanbul (EPI_
ISL_480230). Being present in only three other countries
with one isolate each (UK, India, Australia), in addition
to the USA, this mutation was very likely an introduction
from the USA. Since then, 20 more cases in İstanbul and
3 more cases in Kars were reported, all in April and May.
13620 C>T mutation was first reported in an isolate in
Italy on March 5 and later in South Africa, USA, Denmark,
Belgium, Luxembourg and Singapore by April 6. However,
only three more cases were reported for the rest of April:
two in Italy on April 12, and one in USA on April 28. The
first case with the same mutation in Turkey was reported
in Kars on May 17 and has been reported in 18 more cases,
all in the same city. Initial phylogenetic analysis does
not support introduction of this mutation from abroad,
however, limited sampling makes it difficult to reach a
definitive conclusion. 13620 C>T, 14724 C>T, and 27703
G>T mutations are linked in SARS-CoV-2 genomes from
Turkey, all from a single city (Kars), suggesting a founder
effect and local transmission. It bears noting that each
of the four mutations exclusively found as recurring in

Turkey are limited to a single batch of isolates obtained by
a single center, therefore pending verification.
Afterwards, we sought to understand how the mutation
load of the isolates in Turkey compare to distributions in
other regions. Using our previous date filter, we calculated
the number of single nucleotide variants (SNVs) per
isolate in each region (Table 3). Turkey had the highest
number of SNVs per isolate, followed by South America.
In comparison, Africa, another region which started
sequencing efforts later than the other regions, had a
mean SNV number lower than that of Asia, the region
with the earliest sequences available, implying that the
mutation numbers are strongly influenced by other factors
in addition to the date of introduction of the virus to the
region. We also compared the number of SNVs per isolate
in each region per gene, normalized by kilobase of gene
region (Table 4). Turkey had the most SNVs of any region
in Orf1ab, M, and Orf7a genes, with Orf7a having more
than three times as many SNVs as any other region.
3.2. Database implementation
Data regarding Turkey isolates are available as a database
comprising an interactive phylogenetic tree of the
isolates, a geographical heatmap of sequenced isolates,
and tables for both the mutatome of individual isolates,
and summaries of the mutations observed in the isolates
(Figure). The phylogenetic tree can be viewed both in
real time and divergence time, and colored according
to nucleotide of interest, location, or sequencing date.
The tables are generated using the sequencing metadata
available from GISAID as well as ANNOVAR variant
annotation tables. We aim to regularly validate and update
the database as new sequences are made available7. Future
plans include implementation of Nextstrain clade and
branch information in the phylogenetic tree to aid the user
in comparisons with international sequencing data.
4. Discussion
COVID-19 has been causing tremendous challenges for
clinicians, healthcare systems, societies, and governments,

6
China National Center for Bioinformation (2009). 2019 Novel
Coronavirus Resource (2019nCoVR) [online]. Website https://
bigd.big.ac.cn/ncov/variation/annotation/ [accessed 28 August
2020].

The database is freely accessible at http://covid19.ibg.edu.tr.

7

Table 3. Mean number of variants per isolate in different geographical regions.
Region

Orf1ab

S

Orf3

E

M

Orf6

Orf7a Orf7b Orf8

N

Orf10

Turkey

0.25

0.32

0.49

0.06

0.38

0.03

0.44

0.05

0.11

1.45

0.06

Worldwide

0.19

0.29

0.62

0.08

0.13

0.11

0.11

0.10

0.38

0.84

0.10

Africa

0.21

0.40

0.25

0.06

0.15

0.00

0.06

0.00

0.23

0.75

0.12

Asia

0.20

0.31

0.48

0.11

0.31

0.10

0.13

0.12

0.36

0.83

0.10

Europe

0.18

0.29

0.48

0.09

0.13

0.09

0.12

0.09

0.15

1.10

0.11

North America

0.20

0.26

0.97

0.06

0.09

0.12

0.08

0.12

0.84

0.27

0.11

Oceania

0.19

0.26

0.66

0.05

0.13

0.08

0.07

0.05

0.62

0.75

0.06

South America

0.16

0.33

0.59

0.08

0.06

1.68

0.11

0.14

0.11

1.46

0.06
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Table 4. SNV densities of SARS-CoV-2
genes in different geographical regions.

Turkey

Mean number of
variants per isolate
10.18

Worldwide

8.01

Africa

8.47

Asia

8.53

Europe

7.88

North America

8.20

Oceania

7.54

South America

9.32

Region

and has required development of novel approaches to fight
the pandemic. With an unpredictable future course for the
ongoing pandemic, close monitoring and characterization
of mutations has emerged as top priorities for better
understanding of possible genotype-phenotype relations,
and therefore better management of healthcare efforts.
Mutations in any viral infection, especially those that
have crossed interspecies barriers, have to be considered
in the context of natural selection. As the evolution of a
virus will likely affect its fitness in a new host, any attempts
against such an infection have to consider the causal
relationships between genomic variances and the spread
of the virus. Previous studies suggest that the selective
pressure on mutations in SARS-CoV-2 in human hosts are
largely confined to modest positive selection, with very little
purifying selection, due to the short span of the pandemic,
and that most of the positive selection have occurred in
previous hosts (MacLean et al., 2020). Therefore, any
investigation of the mutations will need to consider most
of the mutations have to be beneficial or neutral to create
true strains of the virus. A comprehensive analysis by
Jungreis et al. (2020) showed that SARS-Cov-2 mutations
are excluded from the evolutionarily conserved amino
acid residues and nucleotides, and the authors concluded
both synonymous and nonsynonymous mutations
are under purifying selection. Therefore, not only the
nonsynonymous mutations, but also the synonymous ones
should be considered as potentially functional.
Many studies already provided lines of evidence that
supports a role for the S D614G mutation in increased
infectivity and likely in transmissibility of SARS-CoV-2
(Daniloski et al., 2020; Korber et al., 2020). It is possible
that new mutations that affect viral behavior may arise,
and therefore emergence and spreading of such mutations
should be monitored closely. However, with tens of millions
affected worldwide, monitoring of every single mutation
is a challenging task. We believe that our database will
provide a valuable and practical resource for researchers
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in Turkey, as well as in other countries, to track the spread
of SARS-CoV-2 mutations in Turkey.
Our findings show the viral isolates in Turkey have
accumulated a higher number of mutations compared
to other regions on average, even after normalizing
for the isolates sequenced earlier during the pandemic
having accumulated fewer mutations. Furthermore, it
has more mutations in the Orf1ab gene, which produces
the polyprotein that is cleaved into the mature peptides
responsible for viral replication, than any other region.
In addition, it has the third highest number of mutations
in the S gene, which is responsible for the viral infection
of the cells. As these two genes have the highest potential
impact on the replication and transmission cycle of the
virus, a higher mutation density in these genes can lead
to an accelerated mutation rate. Of note, the 18877 C>T
mutation in nsp14, the 3’-5’ exonuclease responsible for
error correction during genomic replication, has the
second highest frequency in Turkey of any country6.
Our previous study (Eskier et al., 2020a) shows a strong
correlation between increased mutation density and the
18877 C>T mutation, which might be a potential reason
for Turkey’s increased SNV average per isolate.
Two groups of mutations we identified that is worth
further attention are the 3037 C>T, 14408 C>T, 23403 A>G
haplotype, and the 28881–28883 block mutation. Both of
these groups of mutations are found almost exclusively
together, both in Turkey, and worldwide. In both cases,
Turkey has a higher incidence of mutations in these groups
than worldwide averages, and four of the major regions
(Asia, Europe, North America, Oceania). We previously
found that the 14408 C>T and 23403 A>G mutations,when
occurring together, are strongly associated with increased
mutation density over time (Eskier et al., 2020a), and the
prevalence of both these mutations and the 18877 C>T
mutation in Turkey isolates may further contribute to a
variant-rich mutation landscape (Eskier et al., 2020b).
28881–28883 GGG>AAC is found on the N gene, whose
product is responsible for packaging the genome into
newly produced virions in cells, and regulating host cell
response (McBride et al., 2014). The mutation disrupts
an SR-rich motif in the nucleocapsid protein, which was
found to cause reduced transmissibility in SARS-CoV, a
similar betacoronavirus with high homology to SARSCoV-2 (Tylor et al., 2009; Ayub, 2020). It is not clear
whether the mutation groups are selected together and
show homoplasic recurrence across isolates, or if they are
a result of strong founder effect.
A major concern when analyzing the isolate sequences
from Turkey is the limited nature of the data. The sequences
are few in number, and their geographical and temporal
distributions are highly skewed, leading to difficulty in
understanding the transmission routes of the virus across
the country. Furthermore, new sequences are often made
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Figure. Snapshot of SARS-CoV-2 genome map of Turkey database. Due to size constraints, tables showing information on individual
isolates, or summaries of individual variants, are not included.
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available in large batches by the centers, which further
introduces bias to the samples by potentially generating
sequencing or assembly artifacts to the sequences. Unless
verified by multiple centers, in multiple batches, or by other
experimental methods, caution is required when studying
these mutations. As more genomes are sequenced, a more
clear picture of the SARS-CoV-2 mutatome in Turkey
will emerge and we will likely be able to draw more solid
conclusions.
Finally, it should be noted that mutational profiles of
viral genomes may determine whether infected patients
will develop lasting immunity and remain protected
from re-infection. Although exposure to SARS-CoV-2
protected rhesus macaques from re-infection with the
same strain of virus (Deng et al., 2020), there are questions
still remaining to be answered related to whether each
recovered patient will have lasting immunity. Recent news
within days reported that four patients from Hong Kong,
Belgium, the Netherlands, and USA, who had earlier
recovered from COVID-19 has been reinfected, with a
different strain of SARS-CoV-2 than the original infection8
(Tillett et al., 2021). In support of this observation, an
earlier study reported that convalescent plasma from some
of the COVID-19 patients showed reduced neutralizing
activity against pseudoviruses with D614G mutation in
8
Euronews (1993). Euronews [online]. Website https://www.
euronews.com/2020/08/25/two-cases-of-covid-19-reinfectionreported-in-europe [accessed 28 August 2020].

culture environment (Hue et al., 2020). We do not have
a clear understanding of the viral determinants of lasting
immunity to SARS-CoV-2, however, it seems that certain
viral proteins may be more critical than others, based on
analyses of patient plasma samples. Grifoni et al. (2020)
suggested that M, Spike and N proteins are the major
determinants of CD4+ response, with additional responses
to nsp3, nsp4, ORF3a and ORF8. Hachim et al. (2020)
showed that ORF8, ORF3b and N proteins of SARS-CoV-2
elicited the strongest specific antibody responses in infected
patients. It is plausible that certain mutations within these
proteins affect the immune response, however, it remains
to be explored whether any of the mutations common or
more frequently seen in Turkish isolates have any effect on
the immune response.
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